Harmony Biosciences CMO sells 33,954 shares
Harmony Biosciences Holdings, Inc. (HRMY) reported that Chief Medical Officer Kumar Budur exercised stock options for a total of 22,954 shares of common stock on September 8, 2026, at exercise prices of $30.69 and $30.27 per share.
Rhea-AI Filing Summary
Harmony Biosciences Holdings, Inc. (HRMY) reported that Chief Medical Officer Kumar Budur exercised stock options for a total of 22,954 shares of common stock on September 8, 2026, at exercise prices of $30.69 and $30.27 per share. On September 4 and 8, 2026, he sold an aggregate of 33,954 shares of common stock in open-market transactions at weighted average prices between approximately $41.51 and $43.20 per share. The sales were effected pursuant to a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
8 txns
Insider
Budur Kumar
Role
CHIEF MEDICAL OFFICER
Sold
33,954 shs ($1.45M)
Approx. gross sale proceeds
$1.45M
Approx. exercise cost
$700K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F6 | 12,200 | $0.00 | $0.00 |
| Exercise | Stock Option F7 | 10,754 | $0.00 | $0.00 |
| Sale | Common Stock F1, F3 | 4,500 | $42.2475 | $190K |
| Sale | Common Stock F1, F4 | 1,000 | $42.7947 | $43K |
| Exercise | Common Stock | 12,200 | $30.69 | $374K |
| Exercise | Common Stock | 10,754 | $30.27 | $326K |
| Sale | Common Stock F1, F5 | 22,954 | $43.1014 | $989K |
| Sale | Common Stock F1, F2 | 5,500 | $41.9839 | $231K |
Holdings After Transaction:
Stock Option — 94,546 contracts (Direct);
Common Stock — 13,115 shares (Direct)
Footnotes (7)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.51 to $42.32. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.59 to $42.57. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.59 to $43.02. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.20. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F6. The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date
- F7. The stock option vests with respect to 25% of the underlying shares on May 1, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
Key Figures
Total shares sold: 33,954 shares
Shares sold on September 4, 2026: 5,500 shares
Shares sold at $42.2475 weighted average: 4,500 shares
+5 more
8 metrics
Total shares sold
33,954 shares
Aggregate HRMY common shares sold on September 4 and 8, 2026
Shares sold on September 4, 2026
5,500 shares
Weighted average sale price $41.9839 per share; trades from $41.51 to $42.32
Shares sold at $42.2475 weighted average
4,500 shares
Sales on September 8, 2026 with trades from $41.59 to $42.57
Shares sold at $42.7947 weighted average
1,000 shares
Sales on September 8, 2026 with trades from $42.59 to $43.02
Shares sold at $43.1014 weighted average
22,954 shares
Sales on September 8, 2026 with trades from $43.00 to $43.20
Options exercised at $30.69
12,200 shares
Stock options exercised into common stock on September 8, 2026
Options exercised at $30.27
10,754 shares
Stock options exercised into common stock on September 8, 2026
Total options exercised
22,954 shares
Combined options converted into common stock on September 8, 2026
Key Terms
Rule 10b5-1 trading plan, weighted average price, stock option, vesting
4 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock option financial
"The stock option vests with respect to 25% of the underlying shares"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vesting financial
"remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What insider transactions did HRMY’s chief medical officer report on this Form 4?
The chief medical officer, Kumar Budur, reported exercising stock options for 22,954 shares of Harmony Biosciences common stock and selling 33,954 shares in open-market transactions on September 4 and 8, 2026.
Were the HRMY stock sales made under a Rule 10b5-1 trading plan?
Yes. A footnote states that the sales reported were effected pursuant to a Rule 10b5-1 trading plan, indicating they followed a pre-arranged trading schedule.
What are the vesting terms of the HRMY stock options mentioned in this filing?
One option vests 25% on January 24, 2025, then quarterly until the fourth anniversary of its grant; another vests 25% on May 1, 2025, then quarterly until its fourth anniversary, in each case subject to continued service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
